Viela Bio is a clinical- and emerging commercial-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases. Viela’s approach seeks to redefine the treatment of autoimmune diseases by focusing on critical biological pathways shared across multiple diseases. The Company’s lead product candidate, Inebilizumab, is a humanized monoclonal antibody designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. In addition, the Company has a diverse pipeline of four product candidates focused on a number of other autoimmune diseases with high unmet medical needs, including lupus, Sjögren’s syndrome, IgG4-related disease and myasthenia gravis, as well as other conditions such as kidney transplant rejection.